HOME >> MEDICINE >> NEWS
High fiber intake reduces estrogen levels in Latina women, say Keck School of Medicine researchers

Cohort Study of Diet and Cancer to begin looking at the relationship between dietary fiber and estrogen levels in Mexican-American women, an ethnic group in which dietary fiber intake is higher on average than in most other populations. Even then, says Monroe, she selected for the study those who had the highest and lowest intake levels among all the Mexican-American women.

In the end, Monroe and her colleagues-including Laurence N. Kolonel and Suzanne Murphy, professors at the Cancer Research Center of Hawaii, Brian E. Henderson and Malcolm Pike, professors of preventive medicine at the Keck School of Medicine of USC-looked at blood hormone levels of 252 Latina women participating in the Multiethnic Cohort Study in relation to dietary intakes. Dietary fiber intake was quantified in two ways: (1) from a food frequency questionnaire administered at the time of the blood draw; and (2) from biomarkers of dietary fiber intake found in the blood samples.

What they found was that, as dietary fiber intake increases, levels of estrone and estradiol, two female hormones measured in blood, drop sharply. In addition, the researchers say, they found that as dietary fat intake increased in the women studied, so did the hormone levels. "However, when dietary fiber and fat are both included in the statistical model, only dietary fiber remains a significant predictor of hormone levels," Monroe notes.

The next step, Monroe says, is to see if a higher intake of dietary fiber in these women leads to a lower incidence of breast cancer.

"This study provides clear evidence of an association between dietary fiber intake and circulating hormone levels in postmenopausal Latina women," the researchers note, "and potentially provides a dietary means for lowering a woman's risk of breast cancer."


'"/>

Contact: Jon Weiner
jonweine@usc.edu
323-442-2830
University of Southern California
18-Oct-2004


Page: 1 2

Related medicine news :

1. Preschoolers not getting enough fiber
2. Widespread nerve fiber damage in brains of patients with multiple sclerosis associated with fatigue
3. High-than-average fiber consumption does not affect results of wheat bran fiber trial
4. Study of low-fat, high-fiber diet finds no effect on PSA levels in men over a four-year period
5. Yale researcher finds new clue to what blocks nerve fibers from regrowing following spinal cord injury or disease
6. Eastman gives Clemson University $38 million fiber technology
7. American Heart Association media advisory: long-term intake of dietary fiber and decreased risk of coronary heart disease among women
8. Moderate alcohol intake may reduce risk of dementia in older women
9. Higher folate intake associated with decreased risk of hypertension in women
10. UT Southwestern researchers find calcium intake contributing factor in formation of kidney stones
11. Sufficient evidence for reducing sugar intake to tackle obesity?

Post Your Comments:
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... Orlando, Florida (PRWEB) October 20, 2014 ... fired-up former Gov. Charlie Crist made a brief fundraising ...  in Orlando on Thursday. , Fresh from a debate ... refused to take the stage for the first seven ... podium, the former governor described the incident in one ...
(Date:10/20/2014)... 2014 Women’s health specialist, Dr. Amber ... Gynecology of Columbus, Inc., A Division of MaternOhio Clinical ... more than 100,000 patients annually. Dr. Murphy will provide ... stages of a women’s life. She is accepting new ... Westerville and Dublin. , Dr. Murphy offers a wide ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: